AGP Executive Report
Last update: 9 hours agoPeanut Allergy: Two European-linked treatments reported encouraging trial results in children. UK-linked Aravax said its monthly immunotherapy improved peanut tolerance, with effects persisting six months after treatment; French company DBV reported reduced reaction severity with its daily skin patch. Both remain investigational. Eye Care: Sandoz has launched Lupin’s ranibizumab biosimilar across Europe, excluding Germany, for conditions including wet age-related macular degeneration and diabetic eye disease. Health Access: Caritas says the number of people it assists in Italy whose poverty makes healthcare harder to access rose 69.4% from 2015 to 2025. Women’s Health: Spain plans to introduce paid sick leave for menopause from December. Public Health: The ECDC is preparing to roll out a new disease-surveillance platform in nine countries.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
